Literature DB >> 21444117

Rapid clearance of herpes simplex virus type 2 by CD8+ T cells requires high level expression of effector T cell functions.

Michelle H Nelson1, Melanie D Bird, Chin-Fun Chu, Alison J Johnson, Brian M Friedrich, Windy R Allman, Gregg N Milligan.   

Abstract

CD8(+) T cells are important for resolution of HSV-2 lesions from the female genital epithelium. It is uncertain whether optimal clearance of viruses such as HSV-2 that cause a limited, non-systemic infection solely requires expression of effector functions by infiltrating CD8(+) T lymphocytes, or if the clearance rate is reflective of the expression level of critical effector functions. To address this, CD8(+) T cells from normal OT-I mice or OT-I mice deficient in IFNγ (IFNγ(-/-)) or the IFNγ receptor (IFNγR(-/-)) were activated in vitro in the presence of IFNγ or IL-4 to generate a series of effector populations (Tc1 and Tc2-like respectively) that secreted different levels of IFNγ and expressed different levels of HSV-specific cytolytic function. Compared with Tc1 cells, Tc2-like cells produced the type 2 cytokines IL-4 and IL-5, exhibited decreased IFNγ secretion, diminished proliferation in vitro, and decreased antigen-specific cytolysis in vivo. Clearance of an ovalbumin-expressing HSV-2 strain (HSV-2 tk(-) OVA) by adoptively transferred Tc2-like cells was delayed relative to Tc1 cell recipients. Because donor Tc2-like cells proliferated in vivo and infiltrated the infected genital epithelium similar to Tc1 cells, the diminished virus clearance by Tc2-like effector cells correlated with reduced expression of critical effector functions. Together, these results suggest that high level expression of protective T cell functions by effector T cells is necessary for optimal clearance of HSV-2 from the genital epithelium. These results have important implications for vaccines designed to elicit CD8(+) T cells against viruses such as HSV-2 that infect the genital tract.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21444117      PMCID: PMC3081923          DOI: 10.1016/j.jri.2011.01.013

Source DB:  PubMed          Journal:  J Reprod Immunol        ISSN: 0165-0378            Impact factor:   4.054


  31 in total

1.  In vivo persistence of CD8 polarized T cell subsets producing type 1 or type 2 cytokines.

Authors:  A Cerwenka; L L Carter; J B Reome; S L Swain; R W Dutton
Journal:  J Immunol       Date:  1998-07-01       Impact factor: 5.422

Review 2.  Functions of CD8 T-cell subsets secreting different cytokine patterns.

Authors:  T R Mosmann; L Li; S Sad
Journal:  Semin Immunol       Date:  1997-04       Impact factor: 11.130

3.  Early resolution of herpes simplex virus type 2 infection of the murine genital tract involves stimulation of genital parenchymal cells by gamma interferon.

Authors:  Melanie D Bird; Chin-Fun Chu; Alison J Johnson; Gregg N Milligan
Journal:  J Virol       Date:  2006-10-25       Impact factor: 5.103

4.  Clearance of herpes simplex virus type 2 by CD8+ T cells requires gamma interferon and either perforin- or Fas-mediated cytolytic mechanisms.

Authors:  Melanie E Dobbs; Jane E Strasser; Chin-Fun Chu; Claudia Chalk; Gregg N Milligan
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

Review 5.  The cycle of human herpes simplex virus infection: virus transport and immune control.

Authors:  Anthony L Cunningham; Russell J Diefenbach; Monica Miranda-Saksena; Lidija Bosnjak; Min Kim; Cheryl Jones; Mark W Douglas
Journal:  J Infect Dis       Date:  2006-09-15       Impact factor: 5.226

6.  Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States.

Authors:  Fujie Xu; Maya R Sternberg; Benny J Kottiri; Geraldine M McQuillan; Francis K Lee; Andre J Nahmias; Stuart M Berman; Lauri E Markowitz
Journal:  JAMA       Date:  2006-08-23       Impact factor: 56.272

7.  Interferon-gamma enhances resolution of herpes simplex virus type 2 infection of the murine genital tract.

Authors:  G N Milligan; D I Bernstein
Journal:  Virology       Date:  1997-03-03       Impact factor: 3.616

8.  HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells.

Authors:  Michael R Betts; Martha C Nason; Sadie M West; Stephen C De Rosa; Stephen A Migueles; Jonathan Abraham; Michael M Lederman; Jose M Benito; Paul A Goepfert; Mark Connors; Mario Roederer; Richard A Koup
Journal:  Blood       Date:  2006-02-07       Impact factor: 22.113

9.  T lymphocytes are required for protection of the vaginal mucosae and sensory ganglia of immune mice against reinfection with herpes simplex virus type 2.

Authors:  G N Milligan; D I Bernstein; N Bourne
Journal:  J Immunol       Date:  1998-06-15       Impact factor: 5.422

10.  Migration kinetics and final destination of type 1 and type 2 CD8 effector cells predict protection against pulmonary virus infection.

Authors:  A Cerwenka; T M Morgan; A G Harmsen; R W Dutton
Journal:  J Exp Med       Date:  1999-01-18       Impact factor: 14.307

View more
  9 in total

1.  Patient-Specific Neutralizing Antibody Responses to Herpes Simplex Virus Are Attributed to Epitopes on gD, gB, or Both and Can Be Type Specific.

Authors:  Tina M Cairns; Zhen-Yu Huang; John R Gallagher; Yixin Lin; Huan Lou; J Charles Whitbeck; Anna Wald; Gary H Cohen; Roselyn J Eisenberg
Journal:  J Virol       Date:  2015-06-24       Impact factor: 5.103

2.  Targeting the genital tract mucosa with a lipopeptide/recombinant adenovirus prime/boost vaccine induces potent and long-lasting CD8+ T cell immunity against herpes: importance of MyD88.

Authors:  Xiuli Zhang; Xavier Dervillez; Aziz Alami Chentoufi; Tina Badakhshan; Ilham Bettahi; Lbachir Benmohamed
Journal:  J Immunol       Date:  2012-09-26       Impact factor: 5.422

3.  Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.

Authors:  Michael T Hensel; Jason D Marshall; Michael R Dorwart; Darren S Heeke; Eileen Rao; Padmaja Tummala; Li Yu; Gary H Cohen; Roselyn J Eisenberg; Derek D Sloan
Journal:  J Virol       Date:  2017-04-13       Impact factor: 5.103

4.  Detection of herpes simplex virus type 2 (HSV-2) -specific cell-mediated immune responses in guinea pigs during latent HSV-2 genital infection.

Authors:  Clarice L Perry; Brianne N Banasik; Summer R Gorder; Jingya Xia; Sarah Auclair; Nigel Bourne; Gregg N Milligan
Journal:  J Immunol Methods       Date:  2016-09-19       Impact factor: 2.303

5.  A combined carrier-adjuvant system of peptide nanofibers and toll-like receptor agonists potentiates robust CD8+ T cell responses.

Authors:  Jai S Rudra; Brianne N Banasik; Gregg N Milligan
Journal:  Vaccine       Date:  2017-12-14       Impact factor: 3.641

6.  Evaluation of immunological markers of ovine vaginal irritation: Implications for preclinical assessment of non-vaccine HIV preventive agents.

Authors:  Gregg N Milligan; Gracie Vargas; Kathleen L Vincent; Yong Zhu; Nigel Bourne; Massoud Motamedi
Journal:  J Reprod Immunol       Date:  2017-10-13       Impact factor: 4.054

Review 7.  Combinatorial Herpes Simplex Vaccine Strategies: From Bedside to Bench and Back.

Authors:  Aziz A Chentoufi; Nisha R Dhanushkodi; Ruchi Srivastava; Swayam Prakash; Pierre-Gregoire A Coulon; Latifa Zayou; Hawa Vahed; Hiba A Chentoufi; Kathy K Hormi-Carver; Lbachir BenMohamed
Journal:  Front Immunol       Date:  2022-04-25       Impact factor: 8.786

8.  Consensus HIV-1 FSU-A integrase gene variants electroporated into mice induce polyfunctional antigen-specific CD4+ and CD8+ T cells.

Authors:  Olga Krotova; Elizaveta Starodubova; Stefan Petkov; Linda Kostic; Julia Agapkina; David Hallengärd; Alecia Viklund; Oleg Latyshev; Eva Gelius; Tomas Dillenbeck; Vadim Karpov; Marina Gottikh; Igor M Belyakov; Vladimir Lukashov; Maria G Isaguliants
Journal:  PLoS One       Date:  2013-05-08       Impact factor: 3.240

9.  Functional diversity of human vaginal APC subsets in directing T-cell responses.

Authors:  D Duluc; J Gannevat; E Anguiano; S Zurawski; M Carley; M Boreham; J Stecher; M Dullaers; J Banchereau; S Oh
Journal:  Mucosal Immunol       Date:  2012-11-07       Impact factor: 7.313

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.